Initial Report of a Phase II Trial of Weekly Cetuximab, CBDCA, Paclitaxel, and Daily RT in Patients with Locally Advanced SCCHNM. Suntharalingam, Scott E. Strome, Randall S. Taylor et al.|International Journal of Radiation Oncology*Biology*Physics|2007Cited by 4
Early PEG Tube Placement Improves Nutritional Status and Decreases Hospitalization in Head and Neck Cancer Patients Receiving Definitive ChemoradiationC.E. Rutter, M. Suntharalingam, Susannah Yovino et al.|International Journal of Radiation Oncology*Biology*Physics|2009Cited by 2
Early Toxicity and Response Data From a Phase II Trial of Weekly Cetuximab, CBDCA, Paclitaxel, and Daily RT in Patients With Locally Advanced SCCHNM. Suntharalingam, Scott E. Strome, R.A. Ord et al.|International Journal of Radiation Oncology*Biology*Physics|2007Cited by 2
Site as a Prognostic Factor in Patients With Stage III/IV Squamous Cell Carcinoma of the Head and Neck Following Definitive ChemoradiationK. Carter, M. Suntharalingam, Kathleen Settle et al.|International Journal of Radiation Oncology*Biology*Physics|2007Cited by 2
Tumor Volume Predicts Tumor Control and Survival among Patients with Locally Advanced Head and Neck Cancer undergoing Definitive Chemoradiation TherapyAnna Strongin, M. Suntharalingam, Susannah Yovino et al.|International Journal of Radiation Oncology*Biology*Physics|2009Cited by 1